Relative Mortality and Epoetin Alfa Dose in Hemodialysis Patients

American Journal of Kidney Diseases

Volumn 51, Issue 5, 2008, Pages 865-

  Cotter, Dennis J ^a   Thamer, Mae ^a   Zhang, Yi ^a  

^a Medical Technology and Practice Patterns Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CAUSAL ATTRIBUTION; CAUSE OF DEATH; DISEASE SEVERITY; DOSE RESPONSE; HEMATOCRIT; HEMODIALYSIS; HUMAN; LETTER; MORTALITY; PREDICTION; SURVIVAL; TREATMENT OUTCOME;

ANEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOETIN ALFA; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS;

EID: 43049111080     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2007.12.045     Document Type: Letter

References (4)

1. Bradbury B.D., Wang O., Critchlow C.W., et al. Exploring relative mortality and epoetin alfa dose among hemodialysis patients. Am J Kidney Dis 51 (2008) 62-70
2. Cotter D.J., Stefanik K., Zhang Y., Thamer M., Scharfstein D., and Kaufman J. Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients. J Clin Epidemiol 57 (2004) 1086-1095
3. Zhang Y., Thamer M., Stefanik K., Kaufman J., and Cotter D.J. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 44 (2004) 866-876
4. Cotter D., Zhang Y., Thamer M., Kaufman J., and Hernán M.A. The effect of epoetin dose on hematocrit. Kidney Int 73 (2008) 347-353